Hypersensitivity pneumonitis

disease
On this page

Also known as allergic form of pneumonitisallergic interstitial pneumonitisallergic pneumonitisalveolitis, extrinsic allergicexogen allergic alveolitisextrinsic allergic alveolitisextrinsic allergic pneumonia hypersensitivity pneumonitisHP

Summary

Hypersensitivity pneumonitis (MONDO:0017853) is a disease (an umbrella term covering 14 Mondo subtypes) and 30 clinical trials. Top therapeutic interventions include prednisolone and pirfenidone. A subtype of allergic respiratory disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: Unknown (Worldwide) [Orphanet-validated]
  • Umbrella term: 14 Mondo subtypes
  • Clinical trials: 30

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namehypersensitivity pneumonitis
Mondo IDMONDO:0017853
MeSHD000542
Orphanet31740
DOIDDOID:841
NCITC34369
SNOMED CT37471005
UMLSC0002390
MedGen1446
GARD0000012
MedDRA10001890
NORD761
Is cancer (heuristic)no

Also known as: allergic form of pneumonitis · allergic interstitial pneumonitis · allergic pneumonitis · alveolitis, extrinsic allergic · exogen allergic alveolitis · extrinsic allergic alveolitis · extrinsic allergic pneumonia hypersensitivity pneumonitis · HP · hypersensitivity pneumonitis

Data availability: 1 cell line.

Disease family

This is a subtype of allergic respiratory disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorderallergic respiratory diseasehypersensitivity pneumonitis

Related subtypes (3): allergic asthma, allergic rhinitis, allergic bronchopulmonary aspergillosis

Subtypes (14): ventilation pneumonitis, bagassosis, farmer’s lung disease, malt worker’s lung, cork-handlers’ disease, maple bark strippers’ lung, bird fancier’s lung, mushroom workers’ lung, sick building syndrome, hypersensitivity pneumonitis, familial, idiopathic chronic eosinophilic pneumonia, house allergic alveolitis, non-fibrotic hypersensitivity pneumonitis, fibrotic hypersensitivity pneumonitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Pirfenidone, Prednisolone.

Clinical trials & evidence

Clinical trials

Clinical trials: 30.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified22
PHASE24
PHASE42
PHASE31
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04402177PHASE4UNKNOWNThis Study Aim is to Compare the Effect of Oral Methyl Prednisolone on Different Radiological Patterns of Hypersensitivity Pneumonitis as it Was Found That Not All Patients Get Satisfying Therapeutic Effect After Taking Corticosteroids.
NCT05626387PHASE4UNKNOWNAn RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis
NCT07210008PHASE3NOT_YET_RECRUITINGRandomized Controlled Trial Testing the Efficacy of Corticosteroid Therapy Versus Placebo in Fibrotic Hypersensitivity Pneumonitis
NCT06329401PHASE2RECRUITINGA Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT02631603PHASE2TERMINATEDStop Exogenous Allergic Alveolitis (EAA) in Childhood
NCT04675619PHASE2COMPLETEDEvaluation of the Efficacy of Pirfenidone in Progressive Chronic Hypersensitivity Pneumonitis
NCT04677426PHASE2WITHDRAWN129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study
NCT05365802EARLY_PHASE1RECRUITINGFAPI PET for Lung Fibrosis
NCT03800017Not specifiedRECRUITINGSkeletal Muscle Function in Interstitial Lung Disease
NCT04844359Not specifiedACTIVE_NOT_RECRUITINGA Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis
NCT04896138Not specifiedENROLLING_BY_INVITATIONUniversity of Virginia Natural History Study
NCT05392881Not specifiedRECRUITINGInterstitial Lung Disease Research Unit Biobank
NCT05549635Not specifiedRECRUITINGDatabase and Biobank of Patients With Hypersensitivity Pneumonitis
NCT05727852Not specifiedENROLLING_BY_INVITATIONBreath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
NCT05988437Not specifiedNOT_YET_RECRUITINGContribution of the Indoor Environment Medical Advisor in the Management of Fibrosing Hypersensitivity Pneumonitis
NCT06644144Not specifiedRECRUITINGP4O2 ILD Extension
NCT06811389Not specifiedRECRUITINGReimagining Interventions for Support and Education in Hypersensitivity Pneumonitis
NCT07577115Not specifiedACTIVE_NOT_RECRUITINGOccupational and Environmental Exposures Analysis in Interstitial Lung Diseases.
NCT01237145Not specifiedCOMPLETEDBronchoalveolar Immune Response Determination
NCT01487850Not specifiedCOMPLETEDWind Instruments’ Fungal Contamination
NCT02523833Not specifiedCOMPLETEDSmall Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis
NCT03300583Not specifiedCOMPLETEDToward Self-management in ILD
NCT03747627Not specifiedCOMPLETEDBPF Genetics of ILD Study
NCT03873649Not specifiedCOMPLETEDImmune Response in Hypersensitivity Pneumonitis
NCT04273867Not specifiedCOMPLETEDAssessing Health Related Quality of Life in Hypersensitivity Pneumonitis
NCT04561479Not specifiedUNKNOWNPulmonary Rehabilitation in Patients With Chronic Fibrotic Hypersensitivity Pneumonitis
NCT04961944Not specifiedUNKNOWNHypErsensitiVity PneumonITis: DiseAse Progression Characterization
NCT05458635Not specifiedCOMPLETEDPredictors of Pulmonary Hypertension in Patients With Hypersensitivity Pneumonitis
NCT05723796Not specifiedCOMPLETEDStudy of Nasal Mucosa Histopathological Changes in Chronic Hypersensitivity Pneumonitis
NCT07169253Not specifiedCOMPLETEDPrognostic Score Comparison in IPF and HP

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
PREDNISOLONE43
PIRFENIDONE41